On July 13, 2018 RiMO Therapeutics Inc., a privately held oncology drug development company and a pioneer in Radio-immuno Metal-Organic (RiMO) technology-based cancer immunotherapy, reported that the first patient has been dosed in a Phase 1 study of RiMO-301 in patients with advanced tumors (Press release, Rimo Therapeutics, JUL 13, 2018, View Source [SID1234527720]). RiMO-301 enhances the efficacy of X-ray radiotherapy via the unprecedented radiotherapy-radiodynamic therapy (RT-RDT) mode of action.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Initiation of this study represents not only a significant milestone for RiMO Therapeutics but also the field of nanoscale metal-organic frameworks (nMOFs), as RiMO-301 is the first nMOF-based product to enter clinical trials." said Wenbin Lin, Ph.D., founder and chairman of RiMO and also the James Franck Professor of Chemistry, Radiation & Cellular Oncology, and the Ludwig Center for Metastasis Research at the University of Chicago. "Most importantly, we believe this program has the potential to change the treatment paradigm for some cancer types and significantly benefit patients."
Dr. Lin and coworkers have recently published groundbreaking research on the synergistic effect when combining nMOFs with cancer immunotherapy (Nat. Biomed. Eng., doi:10.1038/s41551-018-0203-4). "We expect that this study will generate important insights about the safety of RiMO-301 with radiation and the potential to enhance therapeutic efficacy in the patient population for whom radiotherapy is only palliative." said Jason Luke, M.D., University of Chicago Medicine.
About the Study
The Phase 1 study is a prospective, open-label, single arm, non-randomized study of RiMO-301 with radiation in patients with advanced tumors. The primary objectives in the study include determining maximum tolerated dose (MTD), pharmacokinetics and preliminary anti-tumor activity of RiMO-301. Please refer to www.clinicaltrials.gov for additional clinical trial details.